For research use only. Not for human consumption.
PeptUptidesPEPTUPTIDES
KPV research vial, front view
10mgAlpha-MSH C-terminal tripeptide

KPV

The C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory activity that appears to be separable from melanocortin receptor signalling.

Purity
99.2%
Lot
PU-8F5D
Format
Lyophilized powder
View COACertificate matched to lot PU-8F5D
$75.00

  • Third-party tested
  • Discreet packaging
  • Same-day shipping
  • Encrypted checkout

For research use only. Not for human consumption.

Mechanism of Action

KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone. Published dissection studies have reported that the anti-inflammatory activity of the parent hormone is retained in this fragment while the pigmentary activity is not, which is the basis for studying the fragment separately.

Uptake work in intestinal epithelium has described transport by the oligopeptide transporter PepT1, with downstream effects on NF-kB-associated inflammatory signalling reported in cell and rodent colitis models. Whether melanocortin receptors are required for the fragment's activity remains contested in the literature.

Research Findings

Studies published in Gastroenterology and Inflammatory Bowel Diseases examined PepT1-mediated uptake and inflammation endpoints in murine colitis models. Related work in the Journal of Pharmacology and Experimental Therapeutics dissected the contribution of the core and C-terminal regions of the parent hormone.

More recent reports have examined nanoparticle and self-assembling delivery formats, keratinocyte models and vascular calcification. The alpha-MSH review literature places the fragment within a broader class of anti-inflammatory melanocortin-derived peptides.

Storage & Reconstitution

Sealed lyophilized vials are stored in the dark. The peptide-formulation literature regards the dry solid as the stable state and the solution as the fragile one: refrigeration at 2-8 degrees C is standard for short holding periods, and minus 20 degrees C or colder for long-term storage. Vials are brought to room temperature before opening so that atmospheric moisture does not condense onto the cold solid. Short unmodified tripeptides such as this are handled as standard lyophilized solids; the primary handling risk is peptidase activity in a non-sterile reconstituted solution.

For reconstitution, the diluent is added slowly down the inner wall of the vial rather than directly onto the cake, and the vial is swirled rather than shaken - agitation at an air-liquid interface is a well-documented driver of peptide aggregation. The solid should dissolve to a clear, particle-free solution; persistent cloudiness or visible particulate indicates the material should not be used.

Reconstituted solution is held at 2-8 degrees C and protected from light. Freeze-thaw cycling is the single most avoidable cause of loss, so where a solution must be frozen it is aliquoted first into single-use volumes. Working aliquots are labelled with the lot number so that any result can be traced back to the certificate of analysis for that lot.

Handling summary

Physical form
Lyophilized powder, sealed vial
Sealed storage
2-8 C short term / -20 C long term
Reconstituted
2-8 C, protected from light
Diluent
Bacteriostatic water, added down the vial wall
Avoid
Shaking, freeze-thaw cycling, direct light

References

Every entry below links to its PubMed record. Publication is not endorsement: several of these papers report limitations, negative findings or adverse events, and they are listed for that reason.

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]